Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review.
Journal: Cureus
Published: March 02, 2026
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.
Journal: British journal of haematology
Published: February 25, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
Journal: The Lancet. Haematology
Published: September 18, 2025
Remission of Chimeric Antigen Receptor T-Cell-Refractory Diffuse Large B-Cell Lymphoma Resolved by Surgery and CD20 Bispecific Therapy.
Journal: Cureus
Published: May 22, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 11, 2025
The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas.
Journal: Clinical advances in hematology & oncology : H&O
Published: January 17, 2025
Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma.
Journal: Transplantation and cellular therapy
Published: January 15, 2025
Last Updated: 09/26/2026